Sanofi-aventis Establishes Strategic Alliance
with MIT’s Center for Biomedical Innovation
- Alliance formed to advance cutting-edge research
and foster collaboration between academia and industry -
Paris, France – May 26, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today a strategic
alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be
known as the sanofi-aventis Biomedical Innovation Program (SABIP) .
The goal of the strategic alliance is to advance knowledge in the area of human health through basic and applied
research and to promote scientific exchange between MIT and sanofi-aventis. The alliance provides sanofi-aventis the
opportunity to develop therapeutic, diagnostic and prognostic applications based on the discoveries made during the
Under the newly announced partnership, the SABIP will support a number of activities over the next 3 years through
the granting of Biomedical Innovation Funding Awards. These financial awards will provide MIT researchers with
focused, flexible and rapidly available support to enable innovative research projects for the development of potential
healthcare solutions for patients.
“As sanofi-aventis continues to transform the focus beyond pharmaceuticals to patient healthcare integrated
solutions, collaborations like SABIP that promote the exchange of scientific knowledge between academia and
industry will play a key role,” said Marc Cluzel, Executive Vice-President, R&D, sanofi-aventis. "By bringing together
the talents and expertise of MIT researchers, who are leaders in engineering and biological sciences, with the
resources of sanofi-aventis, this alliance has the potential to provide innovative solutions to patients such as new drug
delivery devices and technologies."
“MIT and its Center for Biomedical Innovation are very excited about our collaborative research program with sanofi-
aventis. MIT brings strengths in advanced science and engineering relevant